BDTXBlack Diamond Therapeutics, Inc.Signing up patients
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Glioblastoma (GBM) · Newly Diagnosed Glioblastoma · GBM · Glioblastoma Multiforme (GBM) · Glioma · Central Nervous System Diseases · Brain Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 162 (planned)
- Started
- May 5, 2026
- Main results expected
- Nov 2028
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)
Measured over: 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07326566 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC